Human herpes virus 8 in solid organ transplantation

Area of Science:

• Virology
• Oncology
• Immunology

Background:

• Human herpes virus 8 (HHV-8) is geographically restricted, causing neoplastic and nonneoplastic diseases.
• HHV-8 infection establishes lifelong latency, but can reactivate when host immunity is compromised, such as post-organ transplantation.
• Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease are the main malignancies linked to HHV-8.

Purpose of the Study:

• To review the association between HHV-8 and neoplastic diseases, particularly in organ transplant recipients.
• To discuss the risk factors, clinical manifestations, and management strategies for HHV-8-associated malignancies.
• To highlight the current gaps in HHV-8 screening and treatment in the transplant setting.

Main Methods:

• Literature review of HHV-8 epidemiology, pathogenesis, and clinical associations.
• Analysis of HHV-8 prevalence and disease incidence in endemic versus low-prevalent regions.
• Examination of current and potential therapeutic approaches for HHV-8-related conditions.

Main Results:

• Neoplastic disease incidence mirrors HHV-8 seroprevalence, with highest risk in immunocompromised individuals, especially solid organ transplant recipients from endemic areas.
• Transplant recipients may develop Kaposi's sarcoma, primary effusion lymphoma, or Castleman's disease following HHV-8 reactivation or primary infection.
• No standard HHV-8 screening exists for transplant patients; HHV-8 PCR confirms clinical suspicion.

Conclusions:

• Management focuses on reducing immunosuppression; chemotherapy may be needed.
• Sirolimus shows potential due to antiproliferative properties; the role of antivirals is undefined.
• Further research is needed to establish screening protocols and define the role of antiviral therapy for HHV-8 in transplant recipients.